Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

September 10, 2021 Auto Bot Atopic Dermatitis, Clinical Trials, Dermavant, P-III, tapinarof 0

Shots:

  • The first patient has been dosed in a P-III program that consists of P-III ADORING 1/2 and long-term extension ADORING 3 study evaluates the safety and efficacy of tapinarof (1% dosed, qd) vs vehicle-controlled cream in patients aged ≥2yrs. with AD
  • The 1EPs of ADORING 1/2 studies will be the proportion of patients achieving a vIGA-AD of 0 or 1 with at least a 2-grade improvement from baseline @8wks. Additionally, the ADORING 3 study will consist of up to 48wks. with a 7-day safety follow-up period
  • Tapinarof is a steroid-free, cosmetically elegant topical cream & a therapeutic aryl hydrocarbon receptor modulating agent for the treatment of PsO and AD

Click here to read full press release/ article | Ref: Businesswire | Image: PharmaLive

The post Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis first appeared on PharmaShots.